ProteoNic and FyoniBio agree on cooperation We are pleased to share with you that we signed a license agreement with ProteoNic. FyoniBio includes the 2G Unic™ technology as an add-on to our proprietary vector technology platform in our CHOnamite® cell line development platform. By this we emphasize the scope for our clients’ cell line development […]
weiterlesenLast week we were celebrating Medical Laboratory Professionals Week (“Lab Week”) to honor all people who are involved in health care and patient advocacy from the lab site. Lab week is a great time to generate excitement about the laboratory medicine profession while having some fun with the lab team. To have some fun with […]
weiterlesenSuccessful Spin-out of FyoniBio to the newly formed entity FyoniBio GmBH We are very happy to inform you that from 1. February 2022, we continue the service business previously being part of Glycotope GmbH within the new entity FyoniBio GmbH. FyoniBio, now as part of Canton Biologics Group, a leading Chinese CDMO, will continue and […]
weiterlesenBioGenes and FyoniBio Enter a Scientific Cooperation We are happy to announce our collaboration with BioGenes which covers a broad range of services from antibody development to the analysis of clinical samples. The individual expertise of each company makes us ideal partners. The first customer projects are expected to start in the next couple of […]
weiterlesenCSL Behring and FyoniBio Partnering We are happy to have initiated a collaboration with CSL Behring research division for the use of the GlycoExpress (GEX®) technology for recombinant production of proteins. GlycoExpress® is a proven platform technology based on human cells for the production of biopharmaceuticals with a human glycosylation profile.
weiterlesen